YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Aricept
Injured by Aricept?
The FDA has begun examining the results of a study of the drug Aricept, which is used to treat Alzheimer's disease. The study examined 974 patients suffering from dementia. There were 11 deaths among patients taking Aricept as compared to no deaths occurred among those taking the placebo. The study was carried out by Eisai, a Japanese pharmaceutical company that sells Aricept. Aricept is also sold by Pfizer. Susan Bro, a spokeswoman for the FDA, said the agency is examining the results of the study. The agency undertook a review of earlier Aricept studies and found no cause for concern. Medical experts say that the new study should not be written off and that it might indicate that Aricept and similar drugs increase the risks of heart disease, The New York Times reported. An Eisai spokesperson said Aricept is safe and the company is not recommending any changes to the drug's label.More Researched Needed on Aricept and Heart Problems
Last year, a British study concluded that Aricept does not delay the onset of disability or the need for nursing-home care for Alzheimer's patients. The study said the drug provided little overall benefit and was expensive. Dr. Lon Schneider, a professor of psychiatry, neurology and gerontology at the University of Southern California, believes that while no additional large trials of Aricept have found a similar risk, it does not indicate that such a risk is absent. Few trials have followed patients for long enough or included enough patients with serious heart problems.
Legal Help for Aricept Victims
If you or a family member were adversely affected by Aricept, contact Parker & Waichman, LLP for a free case evaluation with a defective drug side effects lawyer. Please fill out the form at the right or call 1-800-LAW-INFO (1-800-529-4636) today.
AriceptRSS Feed
Aricept, Zantac, Detrol, other Anticholinergic Drugs Lined to Mental Impairment in Elderly
May 6, 2008 | Parker Waichman Alonso LLP
Two separate reports written by researchers at Wake Forest University School of Medicine support findings released recently concerning anticholinergic medications like Aricept, Zantac and Detrol. The studies found that anticholinergic drugs may be adversely affecting the thinking skills of older patients, a phenomenon not observed in those patients studied who do not take these medications. The studies also indicate that anticholinergics may cause older patients to experience a...
Eleven Deaths during ARICEPT Trial Raises Concern over FDA Application to Permit Wider Use of the Drug
Mar 20, 2006 | Newsinferno News Staff
An article in the October, 2005, issue of Worst Pills Best Pills Newsletter from the consumer watchdog group, Public Citizen, reported that three Alzheimer’s drugs had been found to be of “questionable “ value in a study published in the British Medical Journal (BMJ) (August 5, 2005). Those drugs were donepezil (ARICEPT), rivastigmine (EXELON), and galantamine (REMINYL). The conclusion reached by Public Citizen was that the study “adds additional evidence to support our...
Company reports 11 deaths in Aricept study
Mar 18, 2006 | Newsday
Eleven patients have died while taking the Alzheimer's drug Aricept in a clinical trial testing the drug as a treatment for vascular dementia, a company official said. Judee Shuler, a spokeswoman for Eisai Co. of Japan, which jointly markets the drug in the United States with New York-based Pfizer, said the difference in mortality between those on the drug and those on a placebo was statistically significant. But she noted that, even so, "This was an unexpectedly low mortality rate,...
Aricept
Quick Facts
Aricept Reference Guide
Generic Name
Donepezil
Date Approved
1996
Manufacturer
Eisai America Inc
Status
On the market Approved Uses
Alzheimer's
Serious Side Effects
Death Related Topics
Defective Drugs
Donepezil
Date Approved
1996
Manufacturer
Eisai America Inc
Status
On the market Approved Uses
Alzheimer's
Serious Side Effects
Death Related Topics
Defective Drugs
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS